SUBSEQUENT EVENTS AND PENDING TRANSACTIONS (Details) (USD $)	0 Months Ended
	Apr. 30, 2013 Metronidazole 1.3%	Jan. 31, 2014 PreCision	Mar. 31, 2014 Medicis Metronidazole 1.3%	Apr. 22, 2014 Allergan Subsequent Event
Subsequent events
Expected per share consideration (in dollars per share)				$ 48.30
Expected shares exchanged per transaction				0.83
Anticipated Financing Commitments To Acquire Businesses Gross				$ 15,500,000,000
Total purchase price		475,000,000
Potential future milestone payments		25,000,000
Sale price of worldwide rights	55,000,000
Period of payment of minimum royalties from commercialization of development product	3 years
Acquired IPR&D			$ 66,600,000